Smoking cessation drug not linked to an increased risk of self harm or depression

Oct 01, 2009

There is no strong evidence that the popular smoking cessation drug varenicline increases the risk of self harm or depression compared to other cessation products, according to new research published on BMJ.com today.

Varenicline is a recently introduced smoking cessation product of proven effectiveness, but there have been concerns that it may increase the risk of and suicide. Despite warnings about the possible increased risks issued by regulatory authorities worldwide, varenicline continues to be used widely.

To provide more evidence, a team of researchers from the University of Bristol and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) compared the risk of self harm among people taking varenicline with the risk of self harm associated with other smoking cessation products bupropion and nicotine replacement therapy (patch, inhaler, gum, tablet or lozenge).

Using data from the General Practice Research Database, 80,660 men and women aged between 18 and 95 years were identified who were prescribed a new course of smoking cessation product between September 2006 and May 2008.

Participants were prescribed either nicotine replacement products for (n=63, 265), varenicline (n=10,973), or bupropion (n=6,422).

All electronic patient records over the period of the prescription and for three months after the date of the last prescription were examined for incidences of fatal and non-fatal self-harm, suicidal thoughts and depression.

After controlling for confounding factors, there was no clear evidence of an increased risk of self harm, or depression associated with either varenicline or bupropion.

The authors caution that although they found no strong evidence of an increased risk of self harm linked to varenicline, "the limited power of the study means we cannot rule out either a halving or a twofold increased risk."

They go on to call for more investigation of varenicline's effect on in other databases and secondary analysis of all adverse event reporting in clinical trials.

They conclude by cautioning that any risks must be balanced against the long term health benefits of stopping smoking and the effectiveness of varenicline as a product.

Source: British Medical Journal (news : web)

Explore further: FDA approves new drug for rare genetic disease

add to favorites email to friend print save as pdf

Related Stories

Smoking cessation therapies more effective than placebos

Jul 14, 2008

Six treatments for smoking cessation perform better than placebos — including varenicline (Chantix®), recently approved for use in Canada — states a team of researchers from McGill University and the University of Montreal ...

FDA: New warning needed for Chantix

Feb 03, 2008

The U.S. Food and Drug Administration Friday called for increased awareness of the health risks of the smoking cessation drug varenicline.

DNA (driver of nicotine addiction)

Jan 29, 2008

Cigarette smoking is the largest preventable source of death and disability in the USA, contributing to ~ 400,000 deaths annually. Despite widespread knowledge of the health dangers, ~ 1 in 8 American adults is a habitual ...

Recommended for you

Boxed warnings are common in novel therapeutics

10 hours ago

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

12 hours ago

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

13 hours ago

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments : 0